Innovation & Entrepreneurship Certificate : Publications since January 2023

%% Ruef, Martin   
@article{fds376930,
   Author = {Wezel, F and Ruef, M},
   Title = {Cracking the Deck: National Origins and Promotions in the
             Dutch East India Company, 1700-1796},
   Journal = {Organization Studies},
   Volume = {forthcoming},
   Publisher = {SAGE Publications},
   Year = {2024},
   Month = {April},
   url = {http://dx.doi.org/10.1177/01708406241248985},
   Doi = {10.1177/01708406241248985},
   Key = {fds376930}
}

@article{fds370633,
   Author = {Ruef, M and Beezer, I},
   Title = {Exoduster Entrepreneurs: Distinctiveness and Segregation in
             Minority Communities},
   Journal = {Social Forces},
   Volume = {102},
   Number = {2},
   Pages = {517-538},
   Publisher = {Oxford University Press},
   Year = {2023},
   Month = {December},
   url = {http://dx.doi.org/10.1093/sf/soad065},
   Doi = {10.1093/sf/soad065},
   Key = {fds370633}
}

@article{fds369635,
   Author = {Ruef, M and Birkhead, C and Aldrich, H},
   Title = {What Can Outliers Teach Us About Entrepreneurial
             Success?},
   Journal = {Journal of Small Business and Enterprise
             Development},
   Volume = {30},
   Number = {6},
   Pages = {1088-1108},
   Publisher = {Emerald},
   Year = {2023},
   Month = {October},
   url = {http://dx.doi.org/10.1108/JSBED-01-2023-0004},
   Doi = {10.1108/JSBED-01-2023-0004},
   Key = {fds369635}
}

@article{fds362840,
   Author = {Ruef, M and Grigoryeva, A},
   Title = {Micro-Segregation and the Jewish Ghetto: A Comparison of
             Ethnic Communities in Germany},
   Journal = {European Journal of Sociology},
   Volume = {64},
   Number = {1},
   Pages = {61-96},
   Publisher = {Cambridge University Press},
   Year = {2023},
   Month = {April},
   url = {http://dx.doi.org/10.1017/S0003975622000340},
   Doi = {10.1017/S0003975622000340},
   Key = {fds362840}
}


%% Toone, Eric J.   
@article{fds372357,
   Author = {Zhao, J and Cochrane, CS and Najeeb, J and Gooden, D and Sciandra, C and Fan, P and Lemaitre, N and Newns, K and Nicholas, RA and Guan, Z and Thaden, JT and Fowler, VG and Spasojevic, I and Sebbane, F and Toone,
             EJ and Duncan, C and Gammans, R and Zhou, P},
   Title = {Preclinical safety and efficacy characterization of an LpxC
             inhibitor against Gram-negative pathogens.},
   Journal = {Sci Transl Med},
   Volume = {15},
   Number = {708},
   Pages = {eadf5668},
   Year = {2023},
   Month = {August},
   url = {http://dx.doi.org/10.1126/scitranslmed.adf5668},
   Abstract = {The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine
             deacetylase LpxC is an essential enzyme in the biosynthesis
             of lipid A, the outer membrane anchor of lipopolysaccharide
             and lipooligosaccharide in Gram-negative bacteria. The
             development of LpxC-targeting antibiotics toward clinical
             therapeutics has been hindered by the limited antibiotic
             profile of reported non-hydroxamate inhibitors and
             unexpected cardiovascular toxicity observed in certain
             hydroxamate and non-hydroxamate-based inhibitors. Here, we
             report the preclinical characterization of a slow,
             tight-binding LpxC inhibitor, LPC-233, with low picomolar
             affinity. The compound is a rapid bactericidal antibiotic,
             unaffected by established resistance mechanisms to
             commercial antibiotics, and displays outstanding activity
             against a wide range of Gram-negative clinical isolates in
             vitro. It is orally bioavailable and efficiently eliminates
             infections caused by susceptible and multidrug-resistant
             Gram-negative bacterial pathogens in murine soft tissue,
             sepsis, and urinary tract infection models. It displays
             exceptional in vitro and in vivo safety profiles, with no
             detectable adverse cardiovascular toxicity in dogs at 100
             milligrams per kilogram. These results establish the
             feasibility of developing oral LpxC-targeting antibiotics
             for clinical applications.},
   Doi = {10.1126/scitranslmed.adf5668},
   Key = {fds372357}
}